Lost Money on Marinus Pharmaceuticals, Inc. (MRNS)? Join Class Action Suit Seeking Recovery

Core Viewpoint - The Gross Law Firm is notifying shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) about a class action lawsuit due to alleged misleading statements and omissions regarding the company's clinical trials [2][3]. Group 1: Allegations - The complaint alleges that during the class period, defendants issued materially false and/or misleading statements and failed to disclose the risk of failing to meet early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE) [3]. - It is claimed that defendants did not disclose that failing to meet the early stopping criteria in the RAISE trial could lead to the cessation of the separate Phase 3 RAISE II trial [3]. - As a result, the statements made by defendants regarding the company's business, operations, and prospects were materially false and misleading, lacking a reasonable basis at all times [3]. Group 2: Next Steps for Shareholders - Shareholders who purchased MRNS shares during the specified class period are encouraged to register for the class action, which includes enrollment in a portfolio monitoring software for status updates [4]. - The deadline for shareholders to seek lead plaintiff status is August 5, 2024, and participation in the case incurs no cost or obligation [4][5]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses due to false or misleading statements that inflated the company's stock [5].